Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.67 |
| ▸ | RAB9A | P51151 | 10/20 | 0.67 |
| ▸ | NPC1 | O15118 | 9/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.67 |
| ▸ | GAA | P10253 | 8/20 | 0.67 |
| ▸ | MEN1 | O00255 | 8/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.67 |
| ▸ | HPGD | P15428 | 7/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.67 |
| ▸ | LMNA | P02545 | 6/20 | 0.67 |
| ▸ | PRNP | P04156 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 6/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 2/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5892826 | 0.81 | SMN1; SMN2 (0.66) | SMN1; SMN2RAB9ANPC1ALDH1A1GAA | |
| SCHEMBL3258678 | 0.78 | MAPT (0.50) | SMN1; SMN2RAB9ANPC1ALDH1A1GAA | |
| SCHEMBL7698118 | 0.78 | SMN1; SMN2 (0.61) | SMN1; SMN2RAB9ANPC1ALDH1A1GAA | |
| SCHEMBL102844 | 0.78 | SMN1; SMN2 (1.00) | SMN1; SMN2RAB9ANPC1ALDH1A1GAA | |
| SCHEMBL9260123 | 0.78 | SMN1; SMN2 (0.61) | SMN1; SMN2RAB9ANPC1ALDH1A1GAA | |
| SCHEMBL2634141 | 0.78 | SMN1; SMN2 (0.61) | SMN1; SMN2RAB9ANPC1ALDH1A1GAA | |
| SCHEMBL2623678 | 0.78 | SMN1; SMN2 (0.61) | SMN1; SMN2RAB9ANPC1ALDH1A1GAA | |
| SCHEMBL7216401 | 0.78 | SMN1; SMN2 (0.61) | SMN1; SMN2RAB9ANPC1ALDH1A1GAA | |
| SCHEMBL23290649 | 0.77 | RAB9A (0.74) | SMN1; SMN2RAB9ANPC1ALDH1A1GAA | |
| SCHEMBL2136794 | 0.77 | ALDH1A1 (1.00) | SMN1; SMN2RAB9ANPC1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4003988-B1 | 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | SERVIER LAB (FR) | 2026-05-20 | — | — | EP | disclosed |
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-13 | — | — | US | disclosed |
| CN-114450283-B | 3, 6-Diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their use as pro-apoptotic agents | 法国施维雅药厂 | 2024-05-07 | — | — | CN | disclosed |
| CN-110452235-B | Fluorine-containing isoxazole compound and preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2023-02-17 | — | — | CN | disclosed |
| CN-109689647-B | Bicyclic heteroaryl substituted compounds | 百时美施贵宝公司 | 2023-01-20 | — | — | CN | disclosed |
| US-20220289734-A1 | 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | LES LABORATOIRES SERVIER (FR) | 2022-09-15 | — | — | US | disclosed |
| EP-4003988-A1 | 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | Les Laboratoires Servier (FR) | 2022-06-01 | — | — | EP | disclosed |
| CN-114450283-A | 3, 6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their use as pro-apoptotic agents | 法国施维雅药厂 | 2022-05-06 | — | — | CN | disclosed |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | disclosed |
| EP-3102203-A2 | ANTIBACTERIAL COMBINATIONS COMPRISING POLYMYXIN | SPERO GYRASE, INC. (US) | 2016-12-14 | — | — | EP | disclosed |
| CN-103443099-B | Regulate composition and the method for FXR | NOVARTIS AG (CH) | 2016-03-23 | — | — | CN | disclosed |
| WO-2015114452-A2 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD (GB) | 2015-08-06 | — | — | WO | disclosed |
| CN-103443099-A | Compositions and methods for modulating FXR | IRM LLC | 2013-12-11 | — | — | CN | disclosed |
| US-20100227859-A1 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH LLC | 2010-09-09 | — | — | US | disclosed |
| EP-2144893-A2 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2010-01-20 | — | — | EP | disclosed |
| WO-2009005460-A1 | SMALL MOLECULE INHIBITORS OF NAVL.7 SODIUM CHANNELS FOR THE TREATMENT OF PAIN DISORDERS | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | WO | disclosed |
| WO-2008137816-A2 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH (US) | 2008-11-13 | — | — | WO | disclosed |
| US-7141596-B2 | Inhibitors of proteins that bind phosphorylated molecules | INCYTE CORPORATION (US) | 2006-11-28 | — | — | US | disclosed |
| US-20050272778-A1 | Inhibitors of proteins that bind phosphorylated molecules | INCYTE CORPORATION | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | F2, F2RL3, F12 | SMN1; SMN2 3957/4885RAB9A 748/4885NPC1 2194/4885 |
| US-20100227859-A1 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | MMP13, MMP2, MMP12 | SMN1; SMN2 2164/4885RAB9A 3446/4885NPC1 1286/4885 |
| US-20050272778-A1 | Inhibitors of proteins that bind phosphorylated molecules | PPP3CA, PPP5C, PPM1A | SMN1; SMN2 4635/4885RAB9A 2842/4885NPC1 3745/4885 |
| US-20220289734-A1 | 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | CASP3, BAX, CASP2 | SMN1; SMN2 2163/4885RAB9A 3388/4885NPC1 1890/4885 |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | F2, F2RL3, F12 | SMN1; SMN2 3957/4885RAB9A 748/4885NPC1 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.